BioStem Technologies announces partnership with Kill Cliff FC

Dais World | 14/12/2022 08:24 PM

BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of placental derived biologics, is pleased to announce that the Company will be a corporate sponsor of Kill Cliff Fight Club (“Kill Cliff FC”), a world-renowned MMA training center based-in Southern Florida.

Kill Cliff FC has more than 80 professional fighters including current and former Champions from the Ultimate Fighting Championship (“UFC”), Bellator MMA, One Championship, and other elite MMA promotions. Under Henri Hooft and Greg Jones, Kill Cliff FC has developed and produced elite fighters such as Michael Chandler, Gilbert Burns, Robbie Lawler, Logan Storley, Aung La Nsang and Gregory Rodrigues.

Jason Matuszewski, Chief Executive Officer of BioStem Technologies Inc. said, “The entire team at BioStem is excited for our products to become an integral part of the MMA community. This sponsorship is a great opportunity for BioStem to show a larger population the benefits of our regenerative therapy products. As a leader in regenerative therapies, our product has the ability to make a positive impact in the recovery of elite professional fighters.”

Henri Hooft, Founder and Head Trainer of Kill Cliff FC, commented “We could not be more excited to collaborate with BioStem to help deliver the best regenerative therapies to our elite fighters. The health and wellness of our professional athletes is of the utmost importance. Now BioStem will be associated with some of the biggest moments in MMA.”

Greg Jones, Co-Founder of Kill Cliff FC, commented “Kill Cliff FC is truly honored to be partnering with BioStem. We have already seen the benefit of BioStem’s regenerative therapy when used to treat Gregory “Robocop” Rodriguez. By providing our professional athletes with the newest regenerative technology, we allow them to worry less about injuries and more about performing at their optimal level.”

About BioStem Technologies, Inc. (OTC PINK: BSEM): BioStem Technologies is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The Company is focused on manufacturing products that change lives, leveraging its proprietary BioRetain^® processing method. BioRetain^® has been developed by applying the latest research in regenerative medicine, focused on maintaining growth factors and preserving tissue structure. BioStem Technologies' quality management system and standard operating procedures have been reviewed and accredited by the American Association of Tissue Banks ("AATB"). These systems and procedures are established per current Good Tissue Practices ("cGTP") and current Good Manufacturing Processes ("cGMP"). Our portfolio of quality brands includes VENDAJE^TM, VENDAJE^TM AC, and VENDAJE^TM OPTIC. Each BioStem Technologies placental allograft is processed at the Company's FDA registered and AATB accredited site in Pompano Beach, Florida. 

Forward-Looking Statements: Except for statements of historical fact, this release also contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements relate to expectations or forecasts of future events. Forward-looking statements may be identified using words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements with respect to the operations of the Company, strategies, prospects and other aspects of the business of the Company are based on current expectations that are subject to known and unknown risks and uncertainties, which could cause actual results or outcomes to differ materially from expectations expressed or implied by such forward-looking statements. These factors include, but are not limited to: (1) the impact of any changes to the reimbursement levels for the Company’s products; (2) the Company faces significant and continuing competition, which could adversely affect its business, results of operations and financial condition; (3) rapid technological change could cause the Company’s products to become obsolete and if the Company does not enhance its product offerings through its research and development efforts, it may be unable to effectively compete; (4) to be commercially successful, the Company must convince physicians that its products are safe and effective alternatives to existing treatments and that its products should be used in their procedures; (5) the Company’s ability to raise funds to expand its business; (6) the Company has incurred significant losses since inception and may incur losses in the future; (7) changes in applicable laws or regulations; (8) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; (9) the Company’s ability to maintain production of its products in sufficient quantities to meet demand; and (10) the COVID-19 pandemic and its impact, if any, on the Company’s fiscal condition and results of operations; You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Although it may voluntarily do so from time to time, the Company undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.